57543-71-2

Usage

Uses

Used in Organic Synthesis:
6-METHOXY-2H-CHROMENE-3-CARBONITRILE is utilized as a key intermediate in organic synthesis for the creation of a variety of chemical products. Its unique structure allows it to participate in numerous chemical reactions, facilitating the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 6-METHOXY-2H-CHROMENE-3-CARBONITRILE is used as a research compound for the development of new drugs and pharmaceutical products. Its distinctive chemical properties make it a promising candidate for the discovery of novel therapeutic agents.
Used in Drug Development:
6-METHOXY-2H-CHROMENE-3-CARBONITRILE holds potential in the development of innovative drugs due to its unique chemical structure. It may contribute to the creation of pharmaceuticals with new mechanisms of action or improved efficacy and safety profiles.
Used in Industrial Applications:
While the primary uses of 6-METHOXY-2H-CHROMENE-3-CARBONITRILE are in organic synthesis and pharmaceutical research, it may also have other industrial applications. However, further research and testing are required to fully explore and understand its potential uses in various industries.

InChI:InChI=1/C11H9NO2/c1-13-10-2-3-11-9(5-10)4-8(6-12)7-14-11/h2-5H,7H2,1H3

Upstream product

• 280-57-9 1,4-diaza-bicyclo[2.2.2]octane 
• 672-13-9 2-hydroxy-5-methoxybenzaldehyde 
• 107-13-1 acrylonitrile 

Downstream Products

• 57543-62-1 3-caboxy-6-methoxy-2H-1-benzopyran 
• 1094472-13-5 SR 3850 
• 182570-28-1 (S)-6-methoxychroman-3-carboxylic acid 
• 182570-26-9 6-methoxy-3,4-dihydro-2H-1-benzopyran-3-carboxylic acid 
• 57543-40-5 6-methoxy-2H-chromene-3-carbaldehyde 
• 76322-25-3 6-methoxychroman-3-one 
• 203987-26-2 3-aminomethyl-6-methoxy-3,4-dihydro-2H-1-benzopyran 

Relevant academic research and scientific papers

Discovery of (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide as potent and isoform selective ROCK2 inhibitors

ROCK1 and ROCK2 are highly homologous isoforms. Accumulated studies indicate that they have distinct different functions, and the development of isoform selective ROCK inhibitors will pave new roads for the treatment of various diseases. In this work, a series of amide-chroman derivatives were synthesized and biologically evaluated in order to develop potent and isoform selective ROCK2 inhibitors. Remarkably, (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide ((S)-7c) possessed ROCK2 inhibitory activity with an IC50 value of 3 nM and 22.7-fold isoform selectivity (vs. ROCK1). Molecular docking indicated that hydrophobic interactions were the key element for the high potency and isoform selectivity of (S)-7c. The binding free energies predicted by MM/GBSA were in good agreement with the experimental bioactivities, and the analysis of individual energy terms suggested that residue Lys105 in ROCK1 or Lys121 in ROCK2 was the key residue for the isoform selectivity of (S)-7c.

Benzopyran compounds and preparation method thereof as well as pharmaceutical composition and use of benzopyran compounds

The invention discloses benzopyran compounds as shown in a formula I, a preparation method of the benzopyran compounds, a composition containing the compounds, and use of the compounds in preparation of a farnesoid X receptor antagonist, a liver protection agent and medicines for preventing and treating hyperlipidemia and diabetes mellitus type II.

Synthesis and biological evaluations of chalcones, flavones and chromenes as farnesoid x receptor (FXR) antagonists

Farnesoid X receptor (FXR), a nuclear receptor mainly distributed in liver and intestine, has been regarded as a potential target for the treatment of various metabolic diseases, cancer and infectious diseases related to liver. Starting from two previously identified chalcone-based FXR antagonists, we tried to increase the activity through the design and synthesis of a library containing chalcones, flavones and chromenes, based on substitution manipulation and conformation (ring closure) restriction strategy. Many chalcones and four chromenes were identified as microM potent FXR antagonists, among which chromene 11c significantly decreased the plasma and hepatic triglyceride level in KKay mice.

Substituted heterocyclic compounds, method for preparing and compositions containing same

The invention relates to compounds of formula (I): wherein: R1, R2and R3are as defined in the description, X is as defined in the description, Y represents an oxygen atom, a sulphur atom, a C(H)qgroup, SO or SO2, n is equal to from 0 to 5, A represents a NR5R6group, and medicinal products containing the same which are useful in treating or in preventing melatoninergic disorders.

Substituted 3-amido and 3-amidoalkylbenzopyran derivatives: Synthesis and pharmacological activity as melatonin ligands

A novel series of melatonin analogues based on the benzopyran nucleus is described. These compounds are prepared in several steps from substituted 2-hydroxybenzaldehydes. Some of these derivatives competitively inhibit 2-[125I]iodomelatonin binding to chicken brain and ovine pars tuberalis membranes although with reduced affinity compared with melatonin.

6- and 8-Hydroxy-3,4-dihydro-3-(dipropylamino)-2H-1-benzopyrans. Dopamine Agonists with Autoreceptor Selectivity

The dopamine agonist profiles of 3,4-duhydro-3-(3-dipropylamino)-2H-1-benzopyran-6- and 8-ol (4 and 5, respectively) were examined.Both 4 and 5 exhibited greater relative affinity for receptors labeled with the dopamine agonist ligand propylnorapomorphine than for those labeled with the dopamine antagonist ligand haloperidol.Both compounds attenuated the simulation of brain dopamine synthesis caused by γ-butyrolactone (GBL) and decreased the firing rate of substantia nigra dopamine neurons in rats.This profile of activity, together with the ability of the dopamine antagonist haloperidol to reverse the inhibition of dopamine neuronal firing, indicate that both compounds are brain dopamine agonists.